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Introduction. Modern techniques of tissue engineering in the treatment of some degenerative diseases suggest the 
prospective viability of the biomedical technologies based on the creation of the equivalent of the damaged tissue 
(organ), including the tissue-engineered construct (TEC) of the endocrine pancreas (EP). Obtaining viable islets 
of Langerhans (IL) from the pancreas is a decisive step towards the creation of a TEC EP. The classic method of 
IL separation is based on enzymatic digestion of pancreatic tissue and further islet purification in ficoll density 
gradient during centrifugation, which adversely affects the morphofunctional state of IL. The aim of the study 
was the development of a method for separating viable pancreatic islets from a fragment of human pancreatic 
tail with different cold ischemia times. Materials and methods. A procedure of IL separation is proposed to be 
conducted without the use of EP tissue collagenase perfusion in the Ricordi chamber at the stage of IL separa-
tion and without ficoll solution with a varying density gradient at the stage of IL purification. Identification of 
IL obtained was performed by dithizone staining. The IL viability was evaluated using the LIVE/DEAD® Cell 
Viability Kit. Histological analysis of the initial material included routine staining methods as well as immuno-
histochemical staining of the main types of islet cells. Results. The morphological study of the EP fragments at 
different times of cold ischemia did not reveal significant differences in the histological presentation of the organ 
parenchyma; the islet structure appeared intact. Vital staining confirmed the separated IL viability in vitro for at 
least 1–3 days. Conclusion. The proposed method of pancreatic tissue treatment allowed to reduce the number 
of stages, thereby minimizing the adverse effects of centrifugation and ficoll on the integrity of IL. It is possible 
to obtain the necessary amount of viable IL from a small EP fragment with the cold ischemia time of up to 19 
hours, which can be used to create a TEC of a pancreas.
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МетОдиКА ВЫделеНиЯ ЖиЗНеСПОСОБНЫХ ОСтрОВКОВ 
лАНГерГАНСА иЗ ФрАГМеНтА ХВОСтОВОЙ чАСти 
ПОдЖелУдОчНОЙ ЖелеЗЫ челОВеКА
А.С. Пономарева, Л.А. Кирсанова, Н.В. Баранова, Г.Н. Бубенцова, И.А. Милосердов, 
Е.А. Волкова, В.И. Севастьянов
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Введение. Современные методы тканевой инженерии в лечении ряда дегенеративных заболеваний позво-
ляют надеяться на перспективность биомедицинских технологий, основанных на создании эквивалента 
поврежденной ткани (органа), в том числе тканеинженерной конструкции (ТИК) эндокринного отдела 
поджелудочной железы (ПЖ). Получение жизнеспособных островков Лангерганса (ОЛ) из поджелудочной 
железы является определяющим шагом на пути создания ТИК ПЖ. Классическая методика выделения ОЛ 
базируется на ферментативном переваривании панкреатической ткани и дальнейшей очистке островков в 
градиенте плотности фиколла при центрифугировании, что неблагоприятно сказывается на морфофунк-
циональном состоянии ОЛ. Цель работы состояла в разработке методики выделения жизнеспособных 
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inTrODucTiOn
Modern techniques of tissue engineering in the treat-
ment of some degenerative diseases [1] suggest the pro-
spective viability of the biomedical technologies based 
on the creation of the equivalent of the damaged tissue 
(organ), including the tissue-engineered construct (TEC) 
of the endocrine pancreas (EP). The significance of this 
issue is indubitable since the worldwide incidence of 
insulin-dependent diabetes mellitus (IDDM) is growing 
annually [2, 3]. The perfection of the traditional treat-
ment method – insulin therapy (the application of re-
combinant monocomponent insulin, the use of insulin 
pump, transdermal hormone delivery, etc.) [4] – does 
not prevent the development of serious diabetes mel-
litus complications, such as diabetic angiopathies and 
neuropathy [5].
It is known that the cellular basis of IDDM develop-
ment is the autoimmune damage to the β-cells of islets 
of Langerhans (IL) of EP, which leads to the depletion 
of pool of those cells and the gradual progressive en-
dogenous insulin deficiency [6, 7]. However, the β-cell 
secretory product is heterogenous and β-cell destruction 
deprives the body not only of endogenous insulin but also 
of biologically active polypeptides such as C-peptide and 
amylin. In a healthy body those polypeptides, secreted 
by β-cells, circulate in blood in concentrations typical for 
hormones. The importance of C-peptide in the treatment 
of IDDM complications is noted in several articles [8]. 
Thus, the animal studies of the diabetes mellitus model 
and clinical trials of IDDM patients show that C-peptide 
is effective at early stages of diabetic nephropathy, reti-
nopathy, and neuropathy. It is thought that the basis of 
the C-peptide positive influence is the stimulation of Na-
K-АТPase. The role of amylin is less studied, although 
it is known that, modulating the insulin secretion, it also 
participates in regulation of blood glucose levels [9]. The 
replacement of defective β-cells via transplantation of 
normal islet cells, secreting the entire spectrum of bio-
logically active peptides, allows to achieve the effect not 
observed with the standard insulin therapy.
IL allotransplantation, considered as an alternative 
to EP transplant in the treatment of IDDM [10, 11], is 
capable to ensure the insulin independence of patients 
without serious surgical intrusion [12, 13]. However, the 
major drawback of pancreatic islet transplantation is the 
low functional activity in many ways related to a number 
of damaging factors during separation and cultivation 
[14], particularly the breach in interaction of islets cells 
with extracellular matrix (ECM) which plays an impor-
tant part in islet functioning. This task may be resolved 
by means of creation of a pancreatic tissue-engineered 
construct (TEC EP) [15], consisting of separated IL and 
the carrier matrix providing the conditions typical of 
native IL microenvironment.
The obtainment of viable islets from the pancreas is 
a decisive step towards the creation of TEC. It is known 
that human IL are very sensitive to separation and are 
easily destroyed [16], while the preservation of islet 
structure is a necessary condition for their functiona-
lity. A pancreatic islet may be viewed as a microorgan 
which contains at least five types of endocrine cells [17] 
with strong paracrine interactions [18] necessary for the 
effective secretory cell activity. Thus it is important to 
minimize the influence of specific processing stages in 
order to avoid the islet fragmentation during separation. 
The classic method of IL separation is based on enzy-
matic digestion of pancreatic tissue and further islet pu-
rification in ficoll density gradient during centrifugation 
[19, 20, 21]. However, certain properties of ficoll such 
as hypertonicity, high viscosity, and possible endotoxin 
presence [22] may adversely affect the morphofunctional 
state of IL.
The aim of the study was the development of a 
method for separating viable pancreatic islets from a 
fragment of human pancreatic tail with different cold 
ischemia times.
панкреатических островков из фрагмента хвостовой части ПЖ человека с учетом сроков холодовой 
ишемии органа. Материалы и методы. Опробована методика выделения ОЛ без применения перфузии 
коллагеназой ткани ПЖ в камере Рикорди на стадии выделения ОЛ и без фиколла с разным градиентом 
плотности на стадии очистки ОЛ. Идентификацию полученных ОЛ проводили с помощью окрашивания 
дитизоном. Жизнеспособность ОЛ определяли с помощью набора LIVE/DEAD® Cell Viability Kit. Гисто-
логическое исследование исходного материала включало рутинные методы окрашивания, а также имму-
ногистохимическое окрашивание основных типов островковых клеток. Результаты. Морфологическое 
исследование фрагментов ПЖ на разных сроках холодовой ишемии не обнаружило существенных раз-
личий гистологической картины паренхимы органа; островковый аппарат при этом выглядел сохранным. 
Прижизненное окрашивание подтверждает жизнеспособность выделенных ОЛ in vitro, по меньшей мере, 
в течение 1–3 суток. Заключение. Предложенный способ дал возможность сократить количество стадий 
обработки панкреатической ткани человека, тем самым минимизировать неблагоприятное воздействие 
центрифугирования и фиколла на сохранность ОЛ. Из небольшого фрагмента ПЖ человека на сроках хо-
лодовой ишемии до 19 ч удается получить необходимое количество жизнеспособных ОЛ, которые могут 
быть использованы при создании ТИК поджелудочной железы.
Ключевые слова: островки Лангерганса, поджелудочная железа человека, тканевая инженерия.
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STuDY MaTerialS anD MeThODS
Source material
EP obtained as a result of multiorgan harvesting from 
post-mortem donors (n = 4) and unsuitable for trans-
plantation was used as a source of IL. The donors were 
men aged 47–64 years, the cold ischemia times after 
harvesting were from 6 to 19 hours (Table 1).
Table 1
Data on pancreas donors
Donor Sex Age, yrs Cold ischemia times, hrs
1 ♂ 58 12
2 ♂ 55 4
3 ♂ 63 6
4 ♂ 47 19
histological and immunohistochemical study 
of human eP
EP samples were studied morphologically using the 
routine histological and immunohistochemical staining 
methods. The material was fixed in 10% buffered forma-
lin solution, dehydrated in alcohols of ascending concen-
trations, xylene, and embedded in paraffin wax. 4–5 μm 
sections were obtained using microtome RM 2245 (Lei-
ca, Germany) with subsequent deparaffinization, rehy-
dration and hematoxylin and eosin staining, as well as 
by Masson’s method.
In order to detect the main types of endocrine cells, 
the IL staining for insulin and glucagon antibodies (Cell 
Marque, USA) was conducted per the standard method 
with horseradish peroxidase, using the visualization sys-
tem Reveal-Biotin-Free Polyvalent DAB (Spring, USA).
The visual control of the degree of purification, iden-
tification, and the monitoring of the cultivation process 
and IL viability were performed using luminescent inver-
ted microscope ТS-100 (Nikon, Japan), equipped with 
digital camera Digital Sight DS-Vi1 (Nikon, Japan).
Separation of islets of langerhans
The modification of a method of IL separation from 
a fragment of human pancreatic tail, based on classic 
protocols with the use of collagenase [19, 20], consists in 
the omission of the EP tissue sample collagenase perfu-
sion in the Ricordi chamber at the stage of IL separation 
and of the ficoll solution at the stage of IL purification.
A small fragment (~2.0 g) of human pancreatic tail 
was placed in a Petri dish under sterile conditions with 
the intraparenchymal injections of collagenase solution 
of type 1A (Sigma-Aldrich, USA) with the dosage of 225 
units/g of pancreatic tissue. The tissue was mechanically 
grinded and incubated for 40 min at 37 °C in a thermo-
stat. The action of collagenase was stopped by adding 
the triple volume of cold (4 °С) Hanks’ solution (Pan-
Eko, Russia). The flask with the disaggregated pancreatic 
tissue was shaken manually during several seconds. The 
resulting EP fragments were filtered through a metal 
sieve with the mesh diameter of 0.4–0.6 mm. A certain 
centrifugation regimen was selected for IL purification.
identification of islets of langerhans
IL were identified by dithizone staining (Sigma-Ald-
rich, USA) immediately after separation. To this end, 
part of the suspension was mixed with dithizone solu-
tion at the ratio of 2:1 and incubated for 20–30 min at 
the temperature of 37 °C. Dithizone selectively stained 
pancreatic islets, while acinar cells remained unstained.
cultivation of islets of langerhans
The IL suspension obtained was resuspended in com-
plete growth medium, containing DMEM/F-12 (PanEko, 
Russia), 10% fetal calf serum (HyClone, USA), Hepes 
(Gibco by Life technologies™, USA), 2 mM of L-glu-
tamine (PanEko, Russia), 1% of antibiotic/antimycotic 
(Gibco by Life technologies™, USA) and introduced 
into 25 cm2 culture flasks (Greiner bio-one, Germany). 
Cultivation was conducted at 37 °С in moist atmosphere 
containing 5% СО2 with daily visual observation and IL 
photography. The culture medium was changed after 2 
days of incubation.
live staining of islets of langerhans
The IL viability was evaluated on Days 1 and 3 using 
the LIVE/DEAD® Cell Viability/Cytotoxicity Kit. (Mo-
lecular probes® by Life technologies™, USA) per the 
manufacturer’s instructions. The LIVE/DEAD® kit con-
tains calcein and ethidium homodimer and allows to 
identify simultaneously live and dead cells by means of 
double fluorescent staining. Calcein easily permeates live 
cells and creates intensive homogenous green fluores-
cence (ex/em ~495 nm/~515 nm). Ethidium homodimer 
permeates cells with damaged membranes and while lin-
king with nucleic acids results in bright-red fluorescence 
in dead cells (ex/em ~495 nm/~635 nm), while being 
excluded by the intact plasma membrane of a live cell.
reSulTS anD DiScuSSiOn
Morphological study of a human eP
A histological study of EP fragments with different 
times of cold ischemia (2 samples had ischemia times 
over 10 hours) did not detect pronounced morphological 
differences in the state of parenchyma on the light-optical 
level, which indicated good organ preservation in storage 
solution Custodiol (Dr. Franz Kӧhler Chemie GmbH, 
Germany). Signs of moderate lipomatosis were detected 
in the majority of samples (Fig. 1, a; 2, a). Sclerosis of 
major interlobular ducts, medium and small intralobular 
ducts was observed in all samples studied (Fig. 1, b; 2, b). 
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The abundance of islets of Langerhans in gland paren-
chyma confirmed the assumption that the majority of 
islets in human EP concentrate in the tail part (Fig. 1, c; 
2, c). The islets usually had a rounded (rarely oblong) 
shape and compact (sometimes lobulated) formation. 
Compact formation was more characteristic of smaller-
sized islets, while lobulation was detected in some larger 
islets. Immunohistochemical staining of main types of 
islet cells (β- and α-cells) demonstrated a positive reac-
tion in all samples studied regardless of source material 
ischemia time (Fig. 1, c, d; 2, c, d). Brown precipitate 
granules abundantly filled insulin-positive β-cells which 
composed the main cellular mass of the islet (Fig. 1, c; 
2, c). The less numerous glucagon-positive α-cells were 
spread mosaically in the islet (Fig. 1, d; 2, d). The data 
obtained indicates the integrity of the islet apparatus and 
the potential for the use of the gland for IL separation 
even with the lengthy time of cold ischemia.
freshly separated islets of langerhans
The proposed modified method of IL separation al-
lowed to obtain a significant amount of islets of various 
sizes which correlates with the morphological presentati-
on of the source tissue. The IL observed via the inverted 
microscope had predominantly a rounded shape with a 
smooth surface. Certain roughness created by the rem-
nants of surrounding exocrine tissue was observed on 
the surface of some islets (Fig. 3, a).
Dithizone staining resulted in the orange-red color 
of the islets, which allowed to identify IL, while the 
remnants of acinar tissue remained unstained (Fig. 3, b).
culturing and live staining of islets of 
langerhans
Observation via the inverted microscope demonstra-
ted that during the first three days of culturing IL preser-
ved the initial external characteristics.
Fig. 1. A histological presentation of human pancreas, the cold ischemia time is less than 10 hours. Red arrows indicate sc-
lerotic interlobular and intralobular ducts; yellow arrows indicate islets of Langerhans: a – hematoxylin and eosin staining; 
b – Masson’s method; c – immunohistochemical staining with anti-insulin human antibodies. Numerous well-granulated 
β-cells in islets of Langerhans are shown (brown arrows); d – immunohistochemical staining with anti-glucagon antibodies. 
Glucagon-positive α-cells in islets of Langerhans (brown arrows). ×100
а b
c d
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Fig. 2. A histological presentation of human pancreas, the cold ischemia time is more than 10 hours. Red arrows indicate 
sclerotic intralobular ducts; yellow arrows indicate islets of Langerhans: a – hematoxylin and eosin staining; b – Masson’s 
method; c – immunohistochemical staining with anti-insulin human antibodies. Numerous well-granulated β-cells in islets of 
Langerhans are shown (brown arrows); d – immunohistochemical staining with anti-glucagon antibodies. Glucagon-positive 
α-cells in islets of Langerhans (brown arrows). ×100
а b
c d
Fig. 3. Freshly separated human islets of Langerhans: a – without staining. ×100; b – dithizone staining. ×200
а b
On the first day of culturing, LIVE/DEAD® staining 
was complicated by the presence of a strong background 
luminance due to the large amount of the acinar tissue 
remnants. Nevertheless, separate live cells in the IL 
structure were clearly visualized (Fig. 4). Red fluores-
cence was demonstrated predominantly by dead acinar 
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(Fig. 5, b, c); the emergence of dead cells with red fluo-
rescence along the live ones (Fig. 5, d).
cOncluSiOn
The proposed method of treatment of human pan-
creatic tissue even after a significant time of organ cold 
Fig. 5. 3-day culture of islets: a – without staining; b, c, d – fluorescent staining with LIVE/DEAD®. ×200
а b
c d
Fig. 4. 1-day culture of islets. Fluorescent staining with LIVE/DEAD®. ×100
cells around islets or in culture medium. On Day 3 of 
culturing the preservation of shape and integrity of the 
majority of the islets was observed via light microscope 
(Fig. 5, a). Only a few of them underwent destruction. 
However, LIVE/DEAD® staining in some IL detected 
the emergence of cavities and signs of fragmentation 
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ischemia allows to separate islets of Langerhans from a 
small EP fragment without using the EP tissue sample 
collagenase perfusion in the Ricordi chamber nor pu-
rifying the islets with the ficoll density gradient. This 
allowed to simplify the method, reduce the number of 
stages of tissue treatment, thereby minimizing the adver-
se effect of centrifugation and ficoll on the IL integrity. 
Live staining confirms viability of IL separated in vitro 
for at least 1–3 days. Thus obtained IL may be used 
in further experimental studies in creation of a human 
TEC EP.
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